Rhythm Pharmaceuticals presented new data showing that pediatric patients with acquired hypothalamic obesity experienced sustained reductions in BMI and BMI-Z scores after 2.5 years of treatment with setmelanotide. The treatment also led to significant improvements in weight categories after one year, with many patients moving to healthier weight classifications. Adverse events were consistent with previous safety profiles, including skin hyperpigmentation and nausea. These findings highlight setmelanotide's potential as a long-term therapy for managing complex pediatric obesity linked to hypothalamic damage.
Autonomize, a healthcare AI platform, has strengthened its leadership by appointing three industry veterans to its Advisory Board and hiring Mike Longacre as Head of Transformation. These moves aim to help healthcare organizations move beyond AI pilo...
Fairfax Financial Holdings has finalized its acquisition of Kennedy-Wilson Holdings at $10.90 per share in cash, led by a consortium including Kennedy Wilson's CEO William McMorrow and affiliates of Fairfax. The Kennedy Wilson management team retains...
Aya Gold & Silver Inc., a Canadian precious metals mining company operating in Morocco, will be added to the VanEck Gold Miners ETF (GDX) effective June 19, 2026. This inclusion marks a significant milestone reflecting the company's growth in product...
Nephros, Inc. emphasizes its ultrafiltration technology's ability to capture microplastics and nanoplastics in water, following the U.S. EPA's April 2026 decision to list microplastics as a priority contaminant under the Safe Drinking Water Act. The ...
After the US and Iran reached a deal expected to reopen the Strait of Hormuz, the world's largest tanker owner, Mitsui OSK Lines, cautions that shipping companies will wait for proof the agreement works before resuming normal traffic. The strait is c...
